Apotex Receives FDA’s Drug Shortage Assistance Award
Apr 19, 2023Recognized for efforts in resolving shortage of varenicline tablets
Toronto, Ontario (April 19, 2023) - Apotex Inc. is pleased to announce that it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA) in recognition of the company’s substantial efforts to resolve a shortage of varenicline tablets.
When the US market experienced a shortage of 0.5 mg and 1 mg varenicline tablets, and in order to reduce the impact to patients from an ongoing recall, the FDA temporarily exercised regulatory flexibility and discretion with respect to Apotex’s importation of Health-Canada approved Apo-Varenicline tablets in the U.S. The award also recognizes the submission and ultimate approval of an abbreviated new drug application (ANDA) for varenicline tablets in the U.S. market.
“We’re proud to receive this important award from the FDA, and to be recognized for our commitment to public health” said Allan Oberman, President and Chief Executive Officer, Apotex. “Our flexible supply chain and North American manufacturing model helped ensure an uninterrupted supply of medicines and demonstrates our focus on increasing access to affordable, high quality products.”
This award recognizes the efforts of drug companies and manufacturers who have worked in cooperation with FDA, and have implemented strategies to help provide a steady supply of medically necessary drugs at a time when critical drug shortages pose a substantial public health threat – delaying, and in some cases even denying, critically needed care for patients. Working with drug companies and manufacturers like Apotex, the FDA helped prevent 317 drug shortages in 2021.
About Apotex Inc.
Apotex is a proudly Canadian-based, global health company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. It exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India. For more information, visit www.apotex.com.
-30-
All media enquiries :
Jordan Berman
Vice-President, Global Corporate Affairs
Apotex Inc.
[email protected]
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.
-
Oct 5, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.